Drug intelligence / Profile preview

NGEN-221

Development stage: Preclinical
Lead developer: NEUVOGEN
Modality: Cell Therapies, Vaccines & Immunotherapeutics

Overview

NGEN-221 is an allogeneic, off-the-shelf whole tumor cell vaccine developed by NEUVOGEN for the treatment of breast cancer. The vaccine is constructed from genetically modified tumor cell lines that utilize NEUVOGEN's proprietary activation technology. This platform is designed to present a comprehensive array of broad tumor antigens to the patient's immune system, rather than targeting a single molecular marker. By presenting these antigens in an activated context, NGEN-221 aims to stimulate a robust and multi-faceted immune response against breast cancer cells.

Other names: NEUVOGEN breast cancer vaccine

Beyond the preview

Go deeper on NGEN-221.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NGEN-221.

Explore the full profile